Gaudi’s Casa Milà/La Pedrera, Barcelona
Barcelona: There’s a lot of choice when it comes to cancer immunotherapy conferences, but an event that caught our attention this year as one that merited coverage is the European Association for Cancer Research (EACR) meeting, Defense is the Best Attack – Immuno-Oncology Breakthroughs taking place in Barcelona this week.
The conference is being held in the basement of La Pedrera, Gaudi’s famous Casa Milà modernist building in Barcelona (right).
It’s such an old building that you’re actually forbidden to plug in any phones or computers to charge them for fear of over-loading the electrics, so it’s an event that requires you to be fully charged upfront!
What were some of the highlights from Day 1? There were some key data and concepts being presented that will grab folks involved in cancer research…
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Paths to success in cancer research
It’s time to pull together some notes, ideas, and clinical data on various biomarkers based on data available from clinical studies in oncology R&D and see how much progress we are making.
Are biomarkers a good path to success in cancer research or are they a gloomy red herring to the road less travelled?
Both answers can be equally true, but how do we tell the difference? Are there any clues that we can use ahead of time to avoid later disappointment?
There have been several early studies that we’ve been following lately with readouts available from numerous cancer conferences, both positive and negative.
Can we learn from the failures and successes of the past to better interpret outcomes from future trials?
To learn more and get a heads up on our latest oncology coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
Hitching a ride on the Powell and Mason tram
Gastrointestinal (GI) cancers comprise quite a wide variety of different tumour types, including those of the oesophagus and stomach, pancreas, small bowel and hepatobiliary tract, as well as the colon, rectum and anus.
With the possible exception of oesophagus and gastric/stomach cancers, this bunch of tumour types are generally colld rather than hot tumours for various reasons.
Aside from some recent forays by immune checkpoint blockade in gastric cancer, this field hasn’t had a lot of startling new developments to get excited about of late.
Are things finally changing?
To learn more and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
The first cancer conference of 2018 is now upon us and after enjoying last year’s event in San Francisco, I wanted to take some time to explore some key abstracts of interest at the ASCO GI meeting, which begins tomorrow.
This conference covers various updates on new developments in oesophageal, gastric, colon, pancreatic and colorectal cancers.
Are there any trials or new developments to get excited about at this year’s GI18 meeting?
To find out and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
National Harbor, MD – Day 2 of #SITC17 brought some interesting highlights on a number of fronts, not all of which may be apparent at present, but there are a few readouts that will have a broader impact going forward.
SITC 2017 Stars?
As we move into an era where we see more combinations evolve in immuno-onology, things are likely to get more confusing rather than less so and it could well be another 3-5 years before things truly settle down and more concrete trends emerge.
Here, we reviewed 10 different areas of interest with a strong clinical relevance and explored the topics further.
Please note that some of these will also have follow-on posts with thought leader interviews and related poster reviews.
To learn more insights on the latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
With the annual meeting of Society for Immunotherapy of Cancer (SITC) fast approaching this week, it’s time for a look at some of the final highlights to watch out for.
In this latest conference preview, we have chosen a dozen key topics of interest that readers may find worth checking out plus an honourable mention for early compounds in development that we may well hear more about going forward.
Some of the early warning signs were offered up in the earlier Previews and with the abstracts now available, things are getting very interesting indeed…
How are things panning out so far with the abstract drop and are the new products in development living up to the hype and expectations?
To learn more insights on the latest Gems from the Poster Hall series, subscribers can log-in or you can click to gain access to BSB Premium Content.
We have a two part mini-series this week exploring an approach on how to boost T cells in cold tumours. There are a number of different ways to do this, including adding them ex vivo such as via CAR T cell therapies, although this technique has yet to yield durable benefit in solid tumours.
So how else can it be done?
We’ve discussed immune agonists, oncolytic viruses and cancer vaccines in the past so now it’s time for something different…
In Part 1 of the series today, we explore the science behind the technology and some of the early clinical data that was recently presented at medical meetings.
In Part 2 tomorrow, we have not one but three, different voices exploring some researchers thoughts on where the approach might go.
It should make for interesting reading!
To learn more about these sentiments and insights, subscribers can log-in or you can purchase access to BSB Premium Content below…